DIRS.INFO The most relevant business & tech news

☆ Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation
▼ + stars: | 2024-11-25 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMizuho's Jared Holz on what Trump's FDA pick means for biotech innovationMizuho's Jared Holz joins 'Fast Money' to talk what's next for biopharma space after president-elect Trump names his pick for FDA head.

Persons: Jared Holz Organizations: FDA, Trump

☆ How RFK Jr's war on obesity in the age of Ozempic could shake up the booming weight-loss industry
▼ + stars: | 2024-11-19 | by ( Rebecca Torrence | Hilary Brueck | ) www.businessinsider.com time to read: +9 min

Robert F. Kennedy Jr.'s proposed appointment to lead the US Department of Health and Human Services could have big consequences for a booming weight-loss market. AdvertisementHis likely appointment comes at a pivotal moment for the weight-loss industry, as long-lasting shortages of drugs like Ozempic come to an end. When Farmbox launched in 2014 to deliver healthy food boxes and educate consumers about nutrition, "nobody wanted to invest in us," Tyrner-Dolce said. Doug Mills-Pool/Getty ImagesKennedy's crusade against Big Food could run up against Trump's pro-corporation agenda, though. AdvertisementWeight-loss companies could get more attention — at a costKennedy's focus on holistic chronic disease care, including obesity care, could see a renewed funding rush to the space.

Persons: Trump, Robert F, Kennedy Jr, Kennedy, he's, Obama, Ashley Tyrner, Dolce, Farmbox, FarmboxRx, Michelle Obama, SAUL LOEB, Kennedy's, Jeff Nobbs, Nobbs, Doug Mills, Elon Musk, Donald Trump Jr, podcaster Joe Polish, Brooke Boyarsky Pratt, There's, Knownwell Pratt, Pratt, John Stanford Organizations: Human Services, US Department of Health, National Institutes of Health, Food and Drug Administration, Trump, Big Pharma, Senate, Novo Nordisk, Centers, Medicare, Services, Getty, Street, Department of Health, US Department of Agriculture, Shack, Business, Big Food, Trump's, KFC, McDonald's, Fox, FDA, Moderna Locations: Pennsylvania, Washington

☆ Beware these stocks that rely on government spending if Musk’s DOGE threatens budgets
▼ + stars: | 2024-11-19 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Given this overhang, Morgan Stanley's sales team created a whole basket of stocks that have a large exposure to government spending. gov Relatively high revenue from government, as estimated by Morgan Stanley Notably, the list mostly excludes defense contractors, as Morgan Stanley expects them to be more insulated from budget cuts. Stocks in the basket include these 10: Moderna and Pfizer are two companies that made the basket. While the average analyst polled by LSEG has a hold rating, the average price target implies the stock will nearly double over the next year. MRNA PFE YTD mountain Moderna and Pfizer, year to date Research and consulting firm Gartner was also included in the Morgan Stanley basket.

Persons: Donald Trump's, Trump, Elon, Vivek Ramaswamy, it's, Morgan, Morgan Stanley, Trump's, Robert F, Kennedy Jr, LSEG, Gartner Organizations: Tesla, Roivant Sciences, Department of Government Efficiency, Intuit, Washington Post, Internal Revenue, gov, Moderna, Pfizer, Human Services, Research, Gartner Locations: Stamford , Connecticut

☆ Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value
▼ + stars: | 2024-11-09 | by ( Kenneth Squire | ) www.cnbc.com time to read: +7 min

It invests in a concentrated portfolio of small and midcap life sciences companies, using activism as a tool to unlock value. A successful drug like Ohtuvayre would not just increase the life expectancies of patients with COPD, but it would lower costs for both health-care providers and COPD patients. Currently, there are over 8.6 million U.S. COPD patients with over 4 million remaining symptomatic despite treatment from the current commercial therapies. In early pooling analysis, Ohtuvayre showed a 41% reduction in exacerbations in COPD patients, almost double brensocatib. When Caligan announced its Verona position last month, the stock was trading at $33.40 per share or a $2.5 billion enterprise value.

Persons: Caligan, David Johnson, Ohtuvayre, Verona's, Verona, MorphoSys, bode, Ken Squire Organizations: Verona Pharma, Caligan Partners, Carlyle Group, FDA, MorphoSys AG, Novartis, pharma, 13D Locations: Verona, London, MorphoSys, Caligan's

☆ Goldman Sachs upgrades BioNTech to buy, sees stock surging more than 25%
▼ + stars: | 2024-11-08 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +1 min

Goldman Sachs is optimistic on BioNTech as a result of a new oncology asset. The bank upgraded shares of the German biotechnology firm to a buy rating from neutral. Analyst Chris Shibutani accompanied the move by hiking his price target to $137 from $90, which implies upside of $27%. BNTX YTD mountain BNTX YTD chart BioNTech can also support an innovative and expansive clinical development program for BNT327 that could challenge the status quo of immune-oncology regimens, Shibutani added. Of the 19 who cover it, 12 have buy or strong buy ratings on BioNTech, LSEG data shows.

Persons: Goldman Sachs, Chris Shibutani, BNTX

Trump defeated Democratic candidate Vice President Kamala Harris, and Republicans claimed a majority of the Senate in elections this week. "We know kind of where the world is headed in a Trump environment because we've seen it before," said Jeffrey Solomon, president of TD Cowen, on CNBC's "Money Movers" Wednesday. One M&A advisor, who also spoke to CNBC anonymously, noted that Trump's disdain for Big Tech companies — historically active deal-makers — might keep them on the sidelines. Apparent GOP opposition to the CHIPS Act means that semiconductor consolidation might be challenging, the advisor noted, while cautioning it is still too early to know what a Trump presidency would mean. That advisor noted that smaller banks had been getting gobbled up for "some time," but that the pace and size of those acquisitions would likely ramp up under a Trump presidency.

Persons: Donald Trum, Ronda Churchill, Donald Trump, Kamala Harris, Jeffrey Solomon, TD Cowen, Solomon, Trump, Lina Khan, Khan, Howard Gutman, Jonathan Miller, —, Jared Holz, Mizuho, Sen, Elizabeth Warren, David Zaslav, David Grogan Organizations: Republican, Nevada GOP, Afp, Getty, Trump, Democratic, Republicans, Biden administration's Department of Justice, Federal Trade Commission, CNBC, Dow Jones, MorganFranklin Consulting, Big Tech, Qualcomm, Intel, Integrated Media, Pharmaceutical, Biotech, Illumina, FTC, Maze Therapeutics, Sanofi, Senate, DOJ, Allen & Company Sun Valley Conference Locations: Florida, Nevada, Las Vegas , Nevada, Ronda, Trump, Sun Valley , Idaho

☆ Industrial AI play Dover falls on a noisy quarter. Here's why we'd buy the dip
▼ + stars: | 2024-10-24 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

Dover on Thursday reported weaker-than-expected third-quarter results, pressuring shares of the industrial conglomerate with ties to AI data centers. Dover Why we own it : We own Dover as an industrial turnaround story with exposure to mega-themes, most notably the data center buildout to support artificial intelligence computing. That created headlines that implied Dover cut its full-year guidance, but in reality executives warned in advance that sales growth and earnings projections would be altered. To be sure, we are restricted from trading Dover's stock for the next 72 hours because Jim Cramer on Thursday mentioned the company on CNBC TV. Dover considers those areas its "growth platforms," and their increasing share of the portfolio carries positive implications for Dover's margins.

Persons: We're, Ingersoll Rand, Dover, Richard Tobin, Tobin, Jim Cramer, DOV, Dover's, —, Danaher, Jim Cramer's, Jim, Jason Marz Organizations: IDEX Corp, Management, CNBC, Dover, Mizuho Securities, Club Locations: Dover, Veralto, Europe

☆ Here are the 5 things that could move the stock market in the week ahead
▼ + stars: | 2024-10-20 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

Earnings drove the stock market higher — can they do it again in the week ahead? But he acknowledged that timing is key because our portfolio discipline mandates that we consider lightening up our stock exposure in an overbought market. In fact, AMD was our worst-performing stock for the entire week, losing more than 7% following the prior week's 1.8% slide. Energy was the worst sector of the week for the market as oil prices sank. In the week ahead, housing numbers are the main draw on the economic front.

Persons: Jim Cramer, ASML, Morgan Stanley, WTI, industrials, We're, Sartorius, Danaher, we're, Stanley Black, Lockheed Martin, Philip Morris, Clark, Baker Hughes, Lam, DOV, CARR, Davidson, Northrop, Edwards Lifesciences, Jim Cramer's, Jim, Stocks, Tuesday's, Spencer Platt Organizations: Dow, Nasdaq, Netflix, Modelo, Corona, Constellation Brands, Taiwan Semiconductor Manufacturing Company, Nvidia, AMD, Broadcom, Club, Abbott Laboratories, Energy, Texas, Honeywell, Danaher, Federal Reserve, Treasury, SAP, Logitech, Verizon, General Motors, GE Aerospace, GE, Lockheed, Quest Diagnostics, Norfolk Southern, Polaris, Seagate Technology, Texas Instruments, Canadian National Railway Company, Boeing, GE Vernova, Fisher, Boston, General Dynamics, Hilton, Lam Research, Business Machines, IBM, Newmont, Viking Therapeutics, Vista Energy, Mattel, O'Reilly Automotive, Whirlpool, American Airlines, United Parcel Service, Southwest Airlines, Tractor Supply Company, Carrier Global, Dow Chemical, DOW, Harley, Union Pacific, Valero Energy, Hasbro, Northrop Grumman, Ryder, Boyd Gaming, Western, Boston Beer Company, York Community Bancorp, Colgate, Palmolive, Newell Brands, Jim Cramer's Charitable, CNBC, NEW, Traders, New York Stock Exchange, Getty Locations: BlackRock, CrowdStrike, U.S, Dover, Freeport, McMoRan, Kimberly, Norfolk, Las, ORLY, VALE, New York City

☆ These 9 biotech stocks have doubled this year and are set to double again, analysts say
▼ + stars: | 2024-10-17 | by ( Ganesh Rao | ) www.cnbc.com time to read: +4 min

Nine health-care stocks have more than doubled in price this year, but still have more than 100% upside potential, according to analysts. All have a "buy" or equivalent rating, and every single one expects the stock to more than double over the next 12 months. The median average price target of $66.50 from eight analysts points to a 252% upside potential over the next 12 months. Benitec is expected to rise by 104% over the next 12 months, according to the median price target of five analysts. Humacyte has doubled this year, and analysts expect it to double again over the next 12 months.

Persons: Benitec, Arcutis, Stocks, Rezolute Rezolute, Trevi, Arcutis Biotherapeutics, Humacyte Organizations: CNBC Pro, Nasdaq, Jasper Therapeutics, Corbus Pharmaceuticals, Rezolute, Trevi Therapeutics, Delcath Systems, Precision Medicines, Jasper Therapeutics Jasper Therapeutics, Pharmaceuticals Corbus Pharmaceuticals, Trevi Therapeutics Trevi Therapeutics, Systems Delcath Systems, Praxis, Medicines Locations: Jasper, Jasper Therapeutics Jasper, Massachusetts, California, U.S, Europe, Australia, Hayward , California

☆ In the competitive world of pharma, companies need to focus on worker well-being to retain top talent, says Ferring's HR exec
▼ + stars: | 2024-10-15 | by ( Julia Hood | ) www.businessinsider.com time to read: +7 min

She said that Ferring has grown more intentional about focusing on worker well-being, which is particularly important for the highly competitive field of healthcare. What are the benefits for companies focused on worker well-being? We've defined well-being in a holistic way, so it's not just about physical well-being; it's also about mental well-being and financial well-being. What advice do you have for other companies that are just getting started thinking about DEI and worker well-being initiatives? What policies demonstrate your focus on worker well-being?

Persons: —, Johnson, JP Morgan, Ferring, We've, it's, I've, we've, you've Organizations: Ferring Pharmaceuticals, Service, gastroenterology, Johnson, American Express, Pharma, pharma Locations: Swiss, Switzerland

☆ Here are Monday's biggest analyst calls: Nvidia, Apple, Amazon, Netflix, Campbell Soup, Gilead, American Express & more
▼ + stars: | 2024-10-07 | by ( Michael Bloom | ) www.cnbc.com time to read: +10 min

Wells Fargo upgrades Gilead to overweight from equal weight Wells says the biopharma company has an attractive setup. Wells Fargo upgrades Canadian National to overweight from equal weight Wells says it sees "accelerating growth" for the railway company. Barclays downgrades Netflix to underweight from equal weight Barclay says the "growth algorithm is getting more complex." Wells Fargo downgrades Amazon to equal weight from overweight Wells says the "positive revision story [is] on pause for Amazon. JPMorgan upgrades Ally Financial to overweight from neutral and downgrades American Express to neutral from overweight JPMorgan downgraded American Express and says it sees "asymmetric risk."

Persons: Jefferies, Wells, Morgan Stanley, it's bullish, Barclay, NFLX, Piper Sandler, Piper, Mizuho, JPMorgan downgrades Lamb Weston, JPMorgan, downgrades Sherwin, Williams, KeyBanc, Bernstein, Campbell, underperform Bernstein, Coupang, CPNG, Barclays downgrades, Avery Dennison, Garmin, Hershey Organizations: Apple, Apple Intelligence LT, UW, Vertiv Holdings, Coty, Barclays, Netflix, MKSI, Mizuho, JPMorgan, Deutsche Bank, Alliance, Deutsche, UBS, NXP, Express, American Express, Barclays downgrades DuPont, DuPont, Bank of America downgrades Constellation Brands, Bank of America, Constellation Brands, Bank of America downgrades Comerica, of America, CMA, Air Products, Hershey Locations: OW, Gilead, Canada, underperform

☆ No need to sell this AI data center play ahead of earnings — and updates on 3 more industrial stocks
▼ + stars: | 2024-10-02 | by ( Morgan Chittum | ) www.cnbc.com time to read: +6 min

Deutsche Bank is striking a cautious tone on Dover 's stock ahead of the industrial conglomerate's upcoming earnings report. Late Tuesday, Deutsche Bank listed Dover as a short-term sell idea, suggesting the company will report underwhelming results that may pressure shares later this month. Other industrial stocks in our portfolio received price target increases this week, including Eaton, Stanley Black & Decker and Honeywell . Both firms raised their price target on the DeWalt owner's stock to $100 a share from $96 while maintaining hold or hold-equivalent ratings. Honeywell's price target was increased only slightly at Deutsche Bank — up merely $1 to $226 a share — and left unchanged at Barclays.

Persons: Jim Cramer, industrials, Barclays –, Stanley Black, Decker, Jim, Dover, Richard Tobin, there's, DOV YTD, DOV, It's, Eaton, Vimal Kapur, Jim Cramer's, SWK Organizations: Deutsche Bank, Federal Reserve, Barclays, Environmental Solutions, Wednesday, Honeywell, Deutsche Bank —, Barclays . Deutsche Bank, CNBC, Luza Locations: Dover, Eaton

☆ The one sector of the stock market that is cheap with upside today
▼ + stars: | 2024-09-29 | by ( Karen Firestone | ) www.cnbc.com time to read: +5 min

The table and chart below illustrate some characteristics of the biopharma stocks. The average price/earnings multiple for the group, using 2025 estimates, is 12.7 times versus 20.6 times for the S & P 500. A major knock on the biopharma group is the limited productivity from their extremely expensive research efforts, other than obesity drugs, over the past twenty-five years. The technology using AI might not be ready yet, particularly related to the complex biology of the human body. Complex programs exist already, such as AlphaFold, which predicts the structure of three-dimensional compounds using data on protein sequences.

Persons: Bristol Myers, Amgen, Eli Lilly, Lilly, Johnson Organizations: CNBC, Merck, Pfizer, Novo Nordisk, JPMorgan Locations: Bristol

☆ Here are Friday's biggest analyst calls: Apple, Tesla, Sunrun, FedEx, Reddit, Amazon, Nio, Capital One, Nike & more
▼ + stars: | 2024-09-20 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Morgan Stanley upgrades Centessa Pharmaceuticals, to overweight from equal weight Morgan Stanley said in its upgrade of Centessa that it's bullish on the biopharma company's narcolepsy treatment. Morgan Stanley downgrades Pepsi to equal weight from overweight Morgan Stanley said it sees "topline softness." Morgan Stanley names Nio a research catalyst idea Morgan Stanley said it's bullish on Nio after the China electric vehicle company debuted its latest model, the L60. Morgan Stanley downgrades FedEx to underweight to from equal weight Morgan Stanley downgraded FedEx following its disappointing earnings report on Thursday. Morgan Stanley reiterates Sunrun as overweight Morgan Stanley said the solar company has more room to run and that it's long term bullish on the company's partnership with Costco.

Persons: Jefferies, Morgan Stanley, Morgan Stanley downgrades Pepsi, Key, it's bullish, Riley, Reddit, Nio, it's, Bernstein downgrades Darden, Bernstein, Olive, DRI, Morgan Stanley downgrades ASML, Wells, Susquehanna, Evercore, Sunrun, Tesla, Mercado Organizations: Duke Energy, Centessa Pharmaceuticals, Amkor, China, UBS, Apple, RBC, FedEx, Deutsche Bank, American Airlines Deutsche, Susquehanna, Darden, Costco, Bank of America, Citi, Nike, Mercado Libre, Clearway Energy Locations: Nio, tailwinds, Olive, Argentina

☆ Here are Thursday's biggest analyst calls: Nvidia, Tesla, Apple, Nio, DoorDash, Robinhood, Alphabet, Micron & more
▼ + stars: | 2024-09-19 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Morgan Stanley reiterates Apple as overweight The firm said iPhone 16 demand may not be as bad as feared after comments from the T-Mobile CEO. Morgan Stanley reiterates Nio as overweight Morgan Stanley said it's bullish on the EV company as Nio unveils its latest mid-sized family model, the L60. " Morgan Stanley reiterates Tesla as overweight Morgan Stanley said it's concerned about the company's robotaxi event but that it's standing by the stock. Morgan Stanley downgrades Elanco to equal weight from overweight Morgan Stanley said it "lacks conviction" in shares of the pet biopharma company. "We are initiating on Coursera (COUR) with a Buy rating and a PO of $11 (44% upside potential).

Persons: Morgan Stanley, Apple, TMUS, Piper Sandler, Robinhood, Piper, KeyBanc, Redburn, Mizuho, Raymond James, Nio, it's bullish, TD Cowen, Cowen, Tesla, it's, Hertz, Wells, Morgan Stanley downgrades Elanco, rideshare Organizations: Mobile, Apple Intelligence, JPMorgan, Gas Sciences, Kodiak Gas Services, Talos Energy, Northern Oil, Nio, Micron, Barclays, UW, Laboratories, Abbott Laboratories, Outfront Media, " Bank of America Locations: Kodiak

☆ Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
▼ + stars: | 2024-09-16 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +9 min

watch nowDrugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough. That can allow the treatment to deliver radiation to cancer cells and spare the rest of the body from the level of damage that comes with many cancer drugs. For Pluvicto, patients come in once every six weeks for up to six treatments. One opportunity Bristol Myers Squibb sees is combining radiopharmaceuticals with existing cancer drugs like immunotherapy, said Robert Plenge, Bristol's chief research officer. But she thinks the technology will become an important part of cancer drugs in the next decade.

Persons: Eli Lilly, They've, Michael Schmidt, Schmidt, Franco Origlia, Jacob Van Naarden, Eli Lilly's, Lilly, Biopharma, Van Naarden, Radiopharmaceuticals, Bristol Myers, Ben Hickey, RayzeBio, Hickey, Victor Bulto, Bulto, Timothy Korytko, Ronald Coy, Sharon, Ronald Coy Ronald Coy, Coy, who's, Coy hasn't, she's, we've, Eli Lilly's Van Naarden, Bristol Myers Squibb, Robert Plenge, Susan Galbraith, Galbraith Organizations: Bristol Myers Squibb, AstraZeneca, Guggenheim Securities, Novartis, NSA, Pharmaceutical, Bassett Healthcare Network, Bristol, Fusion Pharmaceuticals, Guggenheim Locations: Aedea Rome, Italy, radiopharmaceuticals, Swiss, FactSet, Bristol, Indiana, U.S, New York, Bassett

☆ Here are Friday's biggest analyst calls: Nvidia, Netflix, Tesla, Kroger, Arm, Oracle, Eli Lilly, PNC, GE Vernova & more
▼ + stars: | 2024-09-13 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Friday's biggest calls on Wall Street: Raymond James initiates Arm as outperform Raymond James said the semis company is well positioned for AI. Citi downgrades Capri Holdings to neutral from buy Citi said the risk/reward is more balanced for the owner of brands like Michael Kors. UBS reiterates Oracle as buy UBS raised its price target on the stock to $200 per share from $175. The feedback on Oracle's top-line growth was overall positive..." UBS reiterates PNC as buy UBS said the bank is a high conviction idea. " Citi resumes Eli Lilly as buy Citi resumed coverage of the stock and says it's well positioned.

Persons: Raymond James, Jefferies, SLG, CFRA, it's, datopotamab, Michael Kors, haven't, Morgan Stanley, EQT, Citi, Eli Lilly, Lilly, Tesla, BEV, Wells Organizations: Arm Holdings, ARM, Citi, Green, Kroger, Macquarie, Rio Tinto, Deutsche Bank, AstraZeneca, Deutsche, Capri Holdings, Barclays, Garmin, GM, BMO, GE, UBS, Oracle, Oracle's, PNC, JPMorgan, Netflix, JPMorgan downgrades Moderna, Nvidia, NVIDIA Locations: GenAI, New York, Rio, RIO, Las Vegas

☆ Stocks making the biggest moves after hours: Adobe, RH, Oracle and more
▼ + stars: | 2024-09-12 | by ( Hakyung Kim | In Hakyungkim | ) www.cnbc.com time to read: +1 min

Adobe issued a fiscal fourth-quarter revenue forecast in a range between $5.50 billion and $5.55 billion. Guidance for adjusted earnings per share came in at $4.63 to $4.68 per share, while analysts had expected $4.67 in earnings per share. Oracle — The cloud software company advanced nearly 6% after raising its revenue guidance. RH — The home furnishings company surged nearly 19% after posting a top- and bottom-line beat for the fiscal second quarter. RH reported adjusted earnings of $1.69 per share on $830 million in revenue.

Persons: Adobe, LSEG, —, RH, Kevin Clark, Nick Wells Organizations: Oracle, Neurocrine Biosciences, Aptiv, —, U.S . Securities, Exchange Commission

☆ A promising cancer treatment is poised for explosive growth, says Redburn Atlantic. These stocks are on its buy list
▼ + stars: | 2024-09-12 | by ( Michelle Fox | ) www.cnbc.com time to read: +5 min

The latest weapon in the battle against cancer is showing promising results — and it's a growing opportunity for investors, according to Redburn Atlantic. To treat cancer, targeted radiopharmaceutical therapy directly goes after tumors with radiation by binding a radioactive particle to a targeting molecule. Delving into diagnostics There are also opportunities in the radiopharma diagnostics space, according to Redburn Atlantic. It has a "strong pipeline of radionuclides for both diagnosis and therapy," he said. "Lantheus benefits from its focus on this rapidly expanding market, with 78% of revenues from radiopharmaceuticals and related products," Ridley-Day added.

Persons: Ed Ridley, Eli Lilly, Myers, Ridley, Astra's, Lantheus Organizations: Big pharma, Novartis, Mariana Oncology, Biopharma, Myers Squibb, RayzeBio, AstraZeneca, Fusion Pharmaceuticals, GE Healthcare Technologies, Lantheus Holdings, GE Healthcare, GE Locations: Bristol, radiopharmaceuticals

☆ Stocks making the biggest moves midday: Kenvue, Caterpillar, Uber, CrowdStrike and more
▼ + stars: | 2024-08-06 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

Check out the companies making the biggest moves midday: Kenvue — The maker of Band-Aid bandages rallied 14% after beating analysts' estimates for its second quarter. Kenvue, which spun off from Johnson & Johnson last year, posted adjusted earnings of 32 cents per share, versus the 28 cents expected from analysts polled by FactSet. Palantir now anticipates revenue between $2.742 billion and $2.750 billion, up from its previous guidance of $2.68 billion to $2.69 billion. Caterpillar's adjusted earnings totaled $5.99 per share in the second quarter, beating the $5.55 per share estimate from analysts polled by FactSet. CrowdStrike — Shares rose 3% after Piper Sandler upgraded CrowdStrike to overweight from neutral, saying the dip in the cybersecurity stock following the global tech outage is a buying opportunity.

Persons: Johnson, FactSet, Taco Bell, ZoomInfo, LSEG, Lucid, BioMarin, CrowdStrike, Piper Sandler, —, Sarah Min, Sean Conlon, Yun Li, Jesse Pound Organizations: Johnson, FactSet, Revenue, Caterpillar, Lumen Technologies, Molson Coors Beverage —, Technologies, LSEG, Taco, CSX —, CSX, BioMarin Pharmaceutical Locations: China, Shanghai

☆ We're buying more of this tech name and eyeing 6 more stocks as the market drops
▼ + stars: | 2024-08-02 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Following the trade, Jim Cramer's Charitable Trust will own 260 shares of PANW, increasing its weighting to 2.46% from 2.18%. One way we like to think about buying into a sea of red is remembering what our approach would be if the market was in rally mode. So with stocks selling off, we're looking to do some light buying of high-quality companies with great long-term prospects that we've been waiting for the stock prices to come down. Outside of these tech names, there are some other stocks we may have our eyes on next week. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jim Cramer's, we've, Nikesh Arora, — it's, Jim Cramer, Jim Organizations: Palo Alto Networks, PANW, Nvidia, Web Services, DuPont, Federal Reserve, Jim Cramer's Charitable, CNBC Locations: DuPont, Dover, Wells Fargo

☆ Here are Thursday's biggest analyst calls: Meta, Tesla, Reddit, Amazon, Wingstop, Arm, Dollar General, Carvana, Qualcomm, SoFi & more
▼ + stars: | 2024-08-01 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Bank of America reiterates Arm as buy Bank of America said it's sticking with the stock following earnings on Wednesday. Robinson to overweight from neutral JPMorgan upgraded the shipping company following its earnings. Barclays reiterates Meta as overweight Barclays says it's sticking with the Instagram parent following earnings on Wednesday. " Bernstein reiterates Qualcomm as outperform Bernstein says it's sticking with Qualcomm following earnings on Wednesday. Citi reiterates SoFi as buy Citi said it's getting more bullish on the stock following a series of investor meetings.

Persons: Goldman Sachs, Goldman, Morgan Stanley, Zeta, Oppenheimer, Etsy, Baird, Wolfe, Bill.com, Robinson, Raymond James, RDDT, Wells, David Lantz, Zack Fadem, Bernstein, Leerink, Cantor Fitzgerald, Tesla, Cantor, it's bullish, Morgan Stanley downgrades Voya, SoFi, it's Organizations: Mizuho, Bank of America, ARM, Zeta Global, Zeta, JPMorgan, GE, NFL, NBA, MLB, Nascar, Barclays, Meta, Qualcomm, SOX, Elon Musk's, Citi Locations: OW, 2H24, China, bullish

☆ DuPont's recovery gains speed with another catalyst for the stock still looming
▼ + stars: | 2024-07-31 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +9 min

DuPont's water and protection segment may have seen a year-over-year decline in sales, but what matters most is that revenue was up 8% sequentially. Notably, DuPont's Water Solutions and Tyvek medical packaging businesses in China — an economy that's lately been a thorn in the side of so many companies — helped drive the quarter-over-quarter expansion. While there's been speculation that DuPont's water business is attracting interest from peers, management said the company has not had conversations about an outright sale. The range for operating EBITDA was raised to $3.06 billion to $3.11 billion, up from $2.9 billion to $3.05 billion previously. DuPont's third-quarter guidance of roughly $3.2 billion in sales, $815 million in operating EBITDA and adjusted EPS of $1.03 essentially matched expectations.

Persons: FactSet, EBITDA, DuPont's, Jim Cramer, —, It's, Ed Breen, Breen, DuPont, there's, Jim Cramer's, Jim, Jim Graham Organizations: DuPont, PPG Industries, Club, Devices, Solutions, Federal Reserve, Wall, Electronics, Semi Tech, CNBC, Bloomberg, Getty Locations: China, Asia Pacific

☆ Here are Friday's biggest analyst calls: Nvidia, Apple, Tesla, Skechers, Meta, Southwest, Amazon, Sweetgreen, & more
▼ + stars: | 2024-07-26 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Morgan Stanley reiterates Tesla as overweight Morgan Stanley said it's sticking with its overweight rating on Tesla " Tesla AI Infrastructure 'base' is by far the fastest rising part of its asset base." Morgan Stanley downgrades WW International to equal weight from overweight Morgan Stanley downgraded the company formerly known as Weight Watchers due to concerns about free-cash flow. Morgan Stanley initiates CervoMed as overweight Morgan Stanley said it's bullish on shares of the biotech company. " Morgan Stanley downgrades STMicroelectronics to equal weight from overweight Morgan Stanley downgraded the stock following earnings. Morgan Stanley reiterates Meta as overweight Morgan Stanley said buy the dip in shares of Meta.

Persons: Redburn, Lockheed Martin, Raymond James, Apple, it's, Morgan Stanley, Tesla, Piper Sandler, Alexander, Baldwin, Piper, ALEX, TD Cowen, Morgan Stanley downgrades STMicroelectronics, Baird, Meta, Guggenheim, Oppenheimer, Sweetgreen, Stifel, Jefferies, Rosenblatt Organizations: Deutsche Bank, Airlines, Deutsche, Lockheed, Apple, Citi, Amazon, AMC, International, Dianthus Therapeutics, Meta, " Bank of America, underperform Bank of America, Barclays, Microsoft, Aviation, Security, Nvidia, Qualcomm, Pharmaceuticals Locations: NYC, Brunswick

☆ An ugly earnings report from a competitor is good news for Abbott Labs
▼ + stars: | 2024-07-26 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. In the wreckage of Dexcom 's second-quarter earnings report, there's good news for Club holding Abbott Laboratories . As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Stocks, Stanley Black, Decker, Abbott, Dexcom, salesforce, Jim Cramer's, ABT, DOV, Jim Organizations: CNBC, Dow Jones, Nasdaq, Federal, U.S, Club, Abbott Laboratories, Dover, Mizuho Securities Locations: Dover

Search resuls for: "Biopharma"

25 mentions found